| |
BRCA1/2-Aberrant OC (n = 35)
|
Wild-Type OC (n = 76)
|
p-value
|
|---|
|
No.
|
%
|
No.
|
%
| |
|---|
|
Age at diagnosis, years
| | | | | |
|
Median
|
55
| |
64
| |
<0.001a
|
|
Range
|
39–77
| |
41–82
| | |
|
Histology
| | | | | |
|
HGS
|
34
|
97.1
|
70
|
92.1
| |
|
Endometrioid
|
1
|
2.9
|
2
|
2.6
| |
|
Clear Cell
|
0
|
0
|
2
|
2.6
| |
|
Mucinous
|
0
|
0
|
0
| |
0.429b
|
|
LGS
|
0
|
0
|
0
| | |
|
Carcinosarcoma
|
0
|
0
|
2
|
2.6
| |
|
FIGO stage at diagnosis
| | | | | |
|
I
|
1
|
2.9
|
1
|
1.4
| |
|
II
|
3
|
8.6
|
4
|
5.6
| |
|
III
|
23
|
65.7
|
48
|
66.7
|
0.470c
|
|
IV
|
8
|
22.9
|
19
|
26.4
| |
|
NA
|
0
|
0
|
4
| | |
|
Debulking status
| | | | | |
|
<2 cm
|
14
|
42.4
|
23
|
31.5
|
0.282e
|
|
≥2 cm
|
19
|
57.6
|
50
|
68.5
| |
|
NA
|
2
| |
3
| | |
|
Platinum sensitivity at PLD initiation
| | | | | |
|
Sensitive
|
5
|
15.2
|
9
|
12.5
| |
|
Resistant
|
28
|
84.8
|
63
|
87.5
|
0.761d
|
|
NA
|
2
| |
4
| | |
|
No. of chemotherapy lines prior to PLD
| | | | | |
|
≤2
|
25
|
71.4
|
61
|
80.3
|
0.429e
|
|
>2
|
10
|
28.6
|
15
|
19.7
| |
|
Evaluable for PLD response
| | | | | |
|
Evaluable
|
26
|
74.3
|
61
|
80.3
|
0.644e
|
|
Not evaluable
|
9
|
15.7
|
15
|
19.7
| |
- aWelch Two Sample t-test; bFisher’s exact test, HGS versus non-HGS histology; cFisher’s exact test, early (I-II) versus advanced (III-IV) stage at diagnosis; dFisher’s exact test; eChi-squared test; NA, not available
